Literature DB >> 14579220

Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia.

George Gordon1, Hassan Rastegar, Roman Schumann, Judith Deiss-Shrem, William Denman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14579220     DOI: 10.1016/s1053-0770(03)00210-6

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


× No keyword cloud information.
  6 in total

1.  Bivalirudin as an Alternative Anticoagulant for Cardiopulmonary Bypass During Adult Cardiac Surgery-A Change in Practice.

Authors:  Peter Gatt; Samuel Anthony Galea; Walter Busuttil; Charles Grima; Jeffrey Muscat; Yvette Farrugia
Journal:  J Extra Corpor Technol       Date:  2017-03

Review 2.  Cardiopulmonary bypass in patients with pre-existing coagulopathy.

Authors:  William DeBois; Junli Liu; Leonard Lee; Leonard Girardi; Wilson Ko; Anthony Tortolani; Karl Krieger; O Wayne Isom
Journal:  J Extra Corpor Technol       Date:  2005-03

3.  Use of bivalirudin as an anticoagulant during cardiopulmonary bypass.

Authors:  James J Veale; Harry M McCarthy; George Palmer; Cornelius M Dyke
Journal:  J Extra Corpor Technol       Date:  2005-09

4.  Anticoagulation with bivalirudin during deep hypothermic circulatory arrest in a patient with heparin-induced thrombocytopenia.

Authors:  Agamemnon Pericleous; Mostafa Sadek; Mary Fitzmaurice; Constance Caldwell; Kris Natividad; Konstadinos A Plestis
Journal:  Tex Heart Inst J       Date:  2014-12-01

5.  Bivalirudin anticoagulation for cardiopulmonary bypass: an unusual case.

Authors:  Nicolas Nikolaidis; Theodore Velissaris; Sunil K Ohri
Journal:  Tex Heart Inst J       Date:  2007

Review 6.  Antiphospholipid syndrome; its implication in cardiovascular diseases: a review.

Authors:  Ioanna Koniari; Stavros N Siminelakis; Nikolaos G Baikoussis; Georgios Papadopoulos; John Goudevenos; Efstratios Apostolakis
Journal:  J Cardiothorac Surg       Date:  2010-11-03       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.